Cargando…
Response to Comment on Niewczas et al. Circulating Modified Metabolites and a Risk of ESRD in Patients With Type 1 Diabetes and Chronic Kidney Disease. Diabetes Care 2017;40:383–390
| Autores principales: | , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
American Diabetes Association
2017
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5521967/ https://www.ncbi.nlm.nih.gov/pubmed/28733381 http://dx.doi.org/10.2337/dci17-0009 |
| _version_ | 1783252075038113792 |
|---|---|
| author | Niewczas, Monika A. Krolewski, Andrzej S. |
| author_facet | Niewczas, Monika A. Krolewski, Andrzej S. |
| author_sort | Niewczas, Monika A. |
| collection | PubMed |
| description | |
| format | Online Article Text |
| id | pubmed-5521967 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2017 |
| publisher | American Diabetes Association |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-55219672018-08-01 Response to Comment on Niewczas et al. Circulating Modified Metabolites and a Risk of ESRD in Patients With Type 1 Diabetes and Chronic Kidney Disease. Diabetes Care 2017;40:383–390 Niewczas, Monika A. Krolewski, Andrzej S. Diabetes Care e-Letters: Comments and Responses American Diabetes Association 2017-08 2017-07-11 /pmc/articles/PMC5521967/ /pubmed/28733381 http://dx.doi.org/10.2337/dci17-0009 Text en © 2017 by the American Diabetes Association. http://www.diabetesjournals.org/content/licenseReaders may use this article as long as the work is properly cited, the use is educational and not for profit, and the work is not altered. More information is available at http://www.diabetesjournals.org/content/license. |
| spellingShingle | e-Letters: Comments and Responses Niewczas, Monika A. Krolewski, Andrzej S. Response to Comment on Niewczas et al. Circulating Modified Metabolites and a Risk of ESRD in Patients With Type 1 Diabetes and Chronic Kidney Disease. Diabetes Care 2017;40:383–390 |
| title | Response to Comment on Niewczas et al. Circulating Modified Metabolites and a Risk of ESRD in Patients With Type 1 Diabetes and Chronic Kidney Disease. Diabetes Care 2017;40:383–390 |
| title_full | Response to Comment on Niewczas et al. Circulating Modified Metabolites and a Risk of ESRD in Patients With Type 1 Diabetes and Chronic Kidney Disease. Diabetes Care 2017;40:383–390 |
| title_fullStr | Response to Comment on Niewczas et al. Circulating Modified Metabolites and a Risk of ESRD in Patients With Type 1 Diabetes and Chronic Kidney Disease. Diabetes Care 2017;40:383–390 |
| title_full_unstemmed | Response to Comment on Niewczas et al. Circulating Modified Metabolites and a Risk of ESRD in Patients With Type 1 Diabetes and Chronic Kidney Disease. Diabetes Care 2017;40:383–390 |
| title_short | Response to Comment on Niewczas et al. Circulating Modified Metabolites and a Risk of ESRD in Patients With Type 1 Diabetes and Chronic Kidney Disease. Diabetes Care 2017;40:383–390 |
| title_sort | response to comment on niewczas et al. circulating modified metabolites and a risk of esrd in patients with type 1 diabetes and chronic kidney disease. diabetes care 2017;40:383–390 |
| topic | e-Letters: Comments and Responses |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5521967/ https://www.ncbi.nlm.nih.gov/pubmed/28733381 http://dx.doi.org/10.2337/dci17-0009 |
| work_keys_str_mv | AT niewczasmonikaa responsetocommentonniewczasetalcirculatingmodifiedmetabolitesandariskofesrdinpatientswithtype1diabetesandchronickidneydiseasediabetescare201740383390 AT krolewskiandrzejs responsetocommentonniewczasetalcirculatingmodifiedmetabolitesandariskofesrdinpatientswithtype1diabetesandchronickidneydiseasediabetescare201740383390 |